Cargando…

Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis

Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahajan, Khushbu, Grover, Chander, Relhan, Vineet, Tahiliani, Sushil, Singal, Archana, Shenoy, M Manjunath, Jakhar, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231711/
https://www.ncbi.nlm.nih.gov/pubmed/37266092
http://dx.doi.org/10.4103/idoj.idoj_355_22
_version_ 1785051791120924672
author Mahajan, Khushbu
Grover, Chander
Relhan, Vineet
Tahiliani, Sushil
Singal, Archana
Shenoy, M Manjunath
Jakhar, Deepak
author_facet Mahajan, Khushbu
Grover, Chander
Relhan, Vineet
Tahiliani, Sushil
Singal, Archana
Shenoy, M Manjunath
Jakhar, Deepak
author_sort Mahajan, Khushbu
collection PubMed
description Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant dermatophytoses. Treatment of OM is based on guidelines released almost a decade back, in addition to published literature and personal preferences. Hence, an expert group of nail society of India (NSI) worked towards drafting these guidelines aimed at compiling recommendations for pharmacologic treatment of OM, based on scientific evidence, along with practical experience. The group did an extensive analysis of available English language literature on OM published during the period 2014–2022. The evidence compiled was graded and discussed to derive consensus recommendations for practice. Special focus was placed on combination therapies and adjunct therapies, including experience of members, to improve treatment outcomes.
format Online
Article
Text
id pubmed-10231711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-102317112023-06-01 Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis Mahajan, Khushbu Grover, Chander Relhan, Vineet Tahiliani, Sushil Singal, Archana Shenoy, M Manjunath Jakhar, Deepak Indian Dermatol Online J Review Article Onychomycosis (OM) is the commonest cause of dystrophic nails, responsible for upto 50% of cases. Apart from significantly damaging the nails, quality of life, and self-image of the sufferer, it also acts as a reservoir of fungal infections carrying important implications for emerging recalcitrant dermatophytoses. Treatment of OM is based on guidelines released almost a decade back, in addition to published literature and personal preferences. Hence, an expert group of nail society of India (NSI) worked towards drafting these guidelines aimed at compiling recommendations for pharmacologic treatment of OM, based on scientific evidence, along with practical experience. The group did an extensive analysis of available English language literature on OM published during the period 2014–2022. The evidence compiled was graded and discussed to derive consensus recommendations for practice. Special focus was placed on combination therapies and adjunct therapies, including experience of members, to improve treatment outcomes. Wolters Kluwer - Medknow 2023-04-27 /pmc/articles/PMC10231711/ /pubmed/37266092 http://dx.doi.org/10.4103/idoj.idoj_355_22 Text en Copyright: © 2023 Indian Dermatology Online Journal https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Mahajan, Khushbu
Grover, Chander
Relhan, Vineet
Tahiliani, Sushil
Singal, Archana
Shenoy, M Manjunath
Jakhar, Deepak
Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
title Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
title_full Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
title_fullStr Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
title_full_unstemmed Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
title_short Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis
title_sort nail society of india (nsi) recommendations for pharmacologic therapy of onychomycosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231711/
https://www.ncbi.nlm.nih.gov/pubmed/37266092
http://dx.doi.org/10.4103/idoj.idoj_355_22
work_keys_str_mv AT mahajankhushbu nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis
AT groverchander nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis
AT relhanvineet nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis
AT tahilianisushil nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis
AT singalarchana nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis
AT shenoymmanjunath nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis
AT jakhardeepak nailsocietyofindiansirecommendationsforpharmacologictherapyofonychomycosis